Lebrikizumab Positions Itself as a Relevant Choice in Routine Clinical Practice of AD

At the EADV Congress, Dr. Diamant Thaçi, MD, PhD, Professor and Director at the Institute of Inflammation Medicine, University of Lübeck, shared phase 3 data from the ADvocate 1 and 2 trials evaluating lebrikizumab in patients with moderate-to-severe atopic dermatitis. The results demonstrate marked improvements in disease severity and rapid itch reduction, addressing key patient needs. Lebrikizumab is now positioning itself as a relevant option in routine clinical practice.